Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
UBS
McKesson
Dow
Farmers Insurance
Cerilliant
Cantor Fitzgerald
Cipla
Accenture

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,696,206

« Back to Dashboard

Summary for Patent: 7,696,206
Title:2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
Abstract:The application claims a compound of the formula ##STR00001## or a salt, a hydrate, or a hydrate of a salt thereof. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of erectile dysfunction.
Inventor(s): Niewohner; Ulrich (Wermelskirchen, DE), Niewohner, legal representative; Maria (Wermelskirchen, DE), Es-Sayed; Mazen (Langenfeld, DE), Haning; Helmut (Wuppertal, DE), Schenke; Thomas (Bergisch Gladbach, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Keldenich; Jorg (Wuppertal, DE), Bischoff; Erwin (Wuppertal, DE), Perzborn; Elisabeth (Wuppertal, DE), Dembowsky; Klaus (Boston, MA), Serno; Peter (Bergisch Gladbach, DE), Nowakowski; Marc (Wuppertal, DE)
Assignee: Bayer Schering Pharma Aktiengesellschaft (Berlin, DE)
Application Number:12/569,720
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,696,206
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,696,206

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare STAXYN vardenafil hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 200179-001 Jun 17, 2010 DISCN Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF ERECTILE DYSFUNCTION ➤ Sign Up
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-003 Aug 19, 2003 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ERECTILE DYSFUNCTION ➤ Sign Up
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-001 Aug 19, 2003 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ERECTILE DYSFUNCTION ➤ Sign Up
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-002 Aug 19, 2003 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ERECTILE DYSFUNCTION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,696,206

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany197 50 085Nov 12, 1997
Germany198 12 462Mar 23, 1998
Germany198 40 289Sep 04, 1998

Non-Orange Book US Patents Family Members for Patent 7,696,206

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,890,922 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors ➤ Sign Up
6,362,178 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors ➤ Sign Up
7,704,999 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors ➤ Sign Up
7,122,540 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Federal Trade Commission
Baxter
Cerilliant
Moodys
Chinese Patent Office
Johnson and Johnson
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.